The Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority has awarded Cleveland BioLabs [CBLI] a potential $13.3 million contract related to the advanced development of Protectan CBLB502, which mitigates injury to a person from radiation. “This award, together with the $8.9 million contract we received earlier in the year from the Department of Defense, is expected to support the final stages of Protectan CBLB502’s development necessary for submission for FDA (Food and Drug Administration) approval and demonstrates clear and strong support of our product development by two major potential customers,” says Michael Fonstein, president and CEO of Cleveland BioLabs. The company has already demonstrated preclinical efficacy and safety of the drug and has received permission from the FDA to begin Phase I clinical trials in human volunteers. The first year of the three-year award is valued at $3.4 million.
free preview